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Induction of neutralizing antibody response against koala
retrovirus (KoRV) and reduction in viral load in koalas
following vaccination with recombinant KoRV envelope
protein
O Olagoke1, D Miller2, F Hemmatzadeh2, T Stephenson2, J Fabijan2, P Hutt3, S Finch3, N Speight2 and P Timms1
Koala retrovirus (KoRV) infects the majority of Australia’s koalas (Phascolarctos cinereus) and has been linked to several life-
threatening diseases such as lymphoma and leukemia, as well as Chlamydia and thus poses a threat to the continued survival of this
species. While quarantine and antiretroviral drug treatment are possible control measures, they are impractical, leaving vaccination
as the only realistic option. In this study, we examined the effect of a recombinant envelope protein-based anti-KoRV vaccine in two
groups of South Australian koalas: KoRV infected or KoRV free. We report a successful vaccination response in the koalas with no
vaccine-associated side effects. The vaccine induced a significant humoral immune response as well as the production of
neutralizing antibodies in both groups of koalas. We also identified B-cell epitopes that were differentially recognized in KoRV-
infected versus KoRV-free koalas following vaccination. Importantly, we also showed that vaccination had a therapeutic effect on
koalas infected exogenously with KoRV by reducing their circulating viral load. Together, this study highlights the possibility of
successfully developing a vaccine against KoRV infection in koalas.
npj Vaccines  (2018) 3:30 ; doi:10.1038/s41541-018-0066-4
INTRODUCTION
Koala retrovirus (KoRV) is a gammaretrovirus that was identified as
recently as just two decades ago,1 and appears to be spreading
through the Australian koala population, from north to south, with
100% of northern Australian koalas infected but less than 50% of
southern animals currently infected.2 KoRV is currently undergoing
endogenization into the koala genome, and as such is the only
retrovirus currently known to be doing so.3 It is thought that
northern koalas carry both the endogenous and exogenous
variants of KoRV, while KoRV is present in the exogenous form in
southern koalas.2 The existence of KoRV in both endogenous and
exogenous states means that it is capable of being transmitted
both vertically (parent to offspring through the germ line) and
horizontally (between infected animals). There are two main
variants of KoRV currently recognized, KoRV-A and KoRV-B.
Whereas KoRV-A has been shown to exist in both exogenous
and endogenous states, KoRV-B is believed to currently exist only
in the exogenous state, and is found only among northern koalas.
In addition to these two well-described KoRV variants, other
variants, KoRV-C to KoRV-I, have also been described.2,4,5 KoRV-
related lymphomas have been reported in several captive
populations6,7 and, while not as prevalent, also occur in wild
koala populations.8,9 KoRV has also been shown to be associated
with chlamydial disease in wild koalas.8,10 While quarantine and
antiretroviral drug treatment are possible control measures, they
are impractical, leaving the development of an effective KoRV
vaccine as the most realistic option to reduce the threat posed by
KoRV in Australian koalas.
Human as well as animal hosts have previously been shown to
produce immune responses following natural presentation of
retroviral antigens,11–14 although not all of these antibodies are
protective against the establishment of infection. In cases where
natural antibodies are not protective, vaccines may be used to
induce the production of protective immunity, with Feline
Leukemia Virus (FeLV) representing a classic example. Recombi-
nant envelope protein-based vaccines are designed to induce
antibody production against epitopes on the envelope of the
retroviruses, and have been shown to induce not only binding
antibodies but also neutralizing antibodies, in different viral
infection models.15–17 Retroviruses are known to replicate by
inserting their genome into the host genome, and KoRV, in
particular, has been shown to have multiple insertion sites of up to
133 in one investigated koala, with most integrations containing
full-length provirus.18 Upon integration, retroviruses use the host’s
machinery to make copies of themselves. Hence, the induction of
neutralizing antibodies becomes important in preventing virus
entry into the target cell, and thereby preventing infection. Feibig
et al.19 showed that rats and goats can be induced to produce
KoRV-neutralizing antibodies when vaccinated with KoRV envel-
ope protein, and hypothesized that the KoRV envelope protein
may be a suitable vaccine candidate to protect uninfected koalas
against KoRV infection. A critical requirement of a vaccine, besides
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protecting against infection in uninfected animals, is whether it
can reduce the viral load in infected animals. As such, therapeutic
vaccines represent a promising approach in the effort to enhance
immunogenicity, reduce bacterial and viral load in both human
and animal infections, and reduce pathogen associated morbidity
and mortality.20,21
In this study, we investigated the possibility of designing a
vaccine that could prevent KoRV infection as well as clear existing
infections in koalas. To do this, we evaluated the potential of the
transmembrane domain of KoRV envelope protein as a suitable
vaccine candidate against KoRV infection in both exogenously
infected and uninfected South Australian koalas. We showed that
vaccination can be successful for both KoRV-negative and KoRV-
positive koalas. All vaccinated animals produced strong levels of
anti-KoRV antibodies. We also showed that these antibodies had a
neutralizing effect in an in vitro assay, and most importantly, we
showed that vaccination had a therapeutic effect on koalas
infected with KoRV by reducing the circulating viral load. We also
identified B-cell epitopes that were differentially recognized in
KoRV-infected or KoRV-free koalas following vaccination.
RESULTS
KoRV status of trial animals
Using the pol gene PCR assay, three of six koalas (Kp1, Kp2, and
Kp3) tested positive for KoRV infection. Genotyping of the KoRV
infection showed that these three koalas were positive for KoRV-A
but negative for KoRV-B. These three KoRV PCR positive koalas
were determined to be infected with exogenous KoRV-A judging
by the estimated proviral copy number of less than one copy per
cell. The other three koalas (Kn4, Kn5, and Kn6) tested negative for
KoRV (Table 1). None of the koalas in this trial tested positive for
KoRV-B.
KoRV antibody status of all koalas, prior to vaccination
As there are very little existing data on the immune response in
koalas with exogenous KoRV infection, all trial koalas were
characterized for the presence of anti-KoRV antibody prior to
vaccination. We developed two in-house ELISAs using recombi-
nant KoRV envelope protein (rEnv) and a synthetic peptide
spanning the membrane proximal external region (MPER) of the
KoRV envelope protein as antigens (Fig. 1a and b), and used these
assays to evaluate the natural level of serum circulating antibodies
to KoRV in all six koalas. Our results (Fig. 2) show that while one
KoRV-positive koala had a medium-high anti-KoRV rEnv serum IgG
titer, the other two KoRV-positive koalas did not have any natural
anti-KoRV antibodies All three animals were negative for
antibodies against the synthetic MPER peptide.
Vaccine safety
All six vaccinated koalas, aged around 2 years, were monitored
daily throughout the 12-week duration of the trial, with regular
health assessments carried out by veterinarians. No vaccine-
related adverse reactions were observed in any of the koalas,
confirming the safety of the vaccine.
Vaccinated koalas develop a strong anti-KoRV antibody response
Six koalas were divided into two groups (n= 3 per group) based
on their KoRV status as determined by KoRV PCR. The animals
were vaccinated subcutaneously on day zero and then received a
booster dose at 4 weeks. Each vaccine dose contained 50 µg of
rEnv protein, with 250 µg each of PCEP, poly I:C, and 500 µg of
peptide 1002. Using our rEnv ELISA to quantify serum IgG
response at time points 0, 8, and 12 weeks post-vaccination, we
observed the production of strong anti-rEnv antibody levels in all
koalas at 8 and 12 weeks post-vaccination. One KoRV-positive
koala had a particularly high antibody level at weeks 8 and 12,
compared to the other two KoRV-positive koalas (Fig. 3a). All
KoRV-negative koalas had comparable antibody responses at each
time point post-vaccination (Fig. 3b). The average serum IgG titers
Table 1. KoRV infection status of trial koalas confirmed by PCR assays
Koala ID KoRV infection status (by pol gene PCR) Env gene PCR assay
KoRV-A KoRV-B
Kp1 Positive Positive Negative
Kp2 Positive Positive Negative
Kp3 Positive Positive Negative
Kn4 Negative Negative Negative
Kn5 Negative Negative Negative
Kn6 Negative Negative Negative
Fig. 1 Schematics showing KoRV genome and segment of env protein used for vaccination. a Representative KoRV genome showing coding
regions. b Schematic showing segment of env protein used for vaccination, epitope mapping analysis, and membrane proximal external
region (MPER) peptide synthesis. rEnv: recombinant envelope protein used for vaccination. The numbers shown represent corresponding
amino acid number (GenBank: AF151794). c Layout of the transmembrane subunit of KoRV envelope protein showing important regions. The
numbers represent 15mer amino acids peptides overlapping by 12 amino acids. FP fusion peptide, HR1 heptad repeat 1, IS
immunosuppressive domain, HR2 heptad repeat 2, MP membrane proximal external region, TM transmembrane region, CP cytoplasmic
tail, R-P R-peptide
Induction of neutralizing antibody response against
O Olagoke et al.
2













in KoRV-positive and KoRV-negative vaccinated koalas at 0, 8, and
12 weeks post-vaccination were compared using a two-way
ANOVA. The analysis showed that whereas there was no
difference in antibody titers based on KoRV status, post-
vaccination antibody titers were significantly increased at weeks
8 (p= 0.0012) and 12 (p= 0.0183) compared to week 0 (Fig. 3c).
Vaccine-induced production of serum-neutralizing antibodies
The production of serum neutralizing antibodies following
vaccination was investigated by infecting human embryonic
kidney (HEK) 293T cells with KoRV in the presence of pre- or
post-vaccination serum. Genomic DNA from infected
HEK293T cells was extracted after 65 h of infection and analyzed
for KoRV proviral integration. The integration of KoRV into
HEK293T cells was compared between pre-vaccination and post-
vaccination sera. The presence of neutralizing antibodies is
defined as a significant reduction in KoRV infection load in
HEK293T cells in the presence of post-vaccination sera. Post-
vaccination sera from all six vaccinated koalas were able to
significantly neutralize KoRV infection in vitro using a 1:20 serum
dilution (Fig. 4). The level of significance was measured as *p <
0.0001 using Student’s T test (p ≤ 0.05). The reduction in KoRV
Fig. 2 KoRV antibody status pre-vaccination. a Anti-KoRV rEnv serum IgG. b Anti-KoRV MPER Peptide serum IgG response in KoRV-positive (n
= 3) and KoRV-negative (n= 3) animals prior to vaccination. Horizontal bars represent mean end-point titers of serum IgG levels of the three
koalas in each group
Fig. 3 Antibody (IgG) levels expressed as end-point titers in vaccinated KoRV-positive a and vaccinated KoRV-negative b animals at 0, 8, and
12 weeks post-vaccination. c The average serum IgG titers in KoRV-positive and KoRV-negative vaccinated koalas at 0, 8, and 12 weeks post-
vaccination were compared and presented as the mean ± SEM of three koalas in KoRV-positive or KoRV-negative group. The level of
significance was measured as *p= 0.0183, **p= 0.0012 using Student’s T test (p ≤ 0.05)
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infectivity of the 293T cells in the presence of post-vaccination
serum for individual koala ranged from 2- to 3-fold reduction.
Reduced KoRV viral RNA load following vaccination
To determine the efficacy of our vaccine in reducing KoRV viral
load in vivo, KoRV viral RNA load present in plasma at weeks 0, 8,
and 12 post-vaccination was measured using a KoRV envelope
gene-specific one-step RT-qPCR assay. Reduction in viral load was
observed in all three KoRV-positive vaccinated koalas between
weeks 0 and 8 and this further reduced by week 12 (Fig. 5a).
Overall, the average viral load of the vaccinated KoRV-infected
koalas at week 8 represents a 48% reduction while week 12
represents a 79% reduction in the viral load compared to levels at
week 0. To more accurately analyze the reduction in viral load
among the three koalas, KoRV viral load was normalized to a fixed
value, 100, and the mean at each time point was compared using
a one-way ANOVA. The analysis showed a significant reduction in
KoRV viral load at each time point post-vaccination (Fig. 5b). The
level of significance was measured as *p= 0.0003 and **p < 0.0001
using Student’s T test (p ≤ 0.05).
Characterization of individual epitope response in vaccinated
animals
To investigate what linear epitopes are recognized post-vaccina-
tion, we designed 63 overlapping 15mer peptides with three
amino acids offset to span the full length of the ecto- and endo-
domains of the p15E subunit of KoRV envelope protein. Each
biotinylated peptide contained a hydrophilic tetrapeptide, SGSG,
between the biotin and sequence of interest. Peptides 1–46 and
peptides 27–63 represent the ecto-domain and endo-domain,
respectively, of the KoRV envelope protein p15E subunit. Using a
newly developed peptide ELISA, the response of each pre-
vaccination sample was compared against its 8 weeks post-
vaccination sample. For the KoRV-negative koalas evaluated,
vaccination resulted in similar responses pre- and post-
vaccination for peptides 1–48, indicating that these epitopes
were not recognized. Peptides 49–63, representing the endo-
domain, however, showed an increased response post-
vaccination. When plasma samples from KoRV-positive animals
were evaluated against the same set of peptides, the antibody
profiles were markedly different from that of the KoRV-negative
animals. While six epitopes present in the endo-domain sequence,
also recognized by the KoRV-negative koalas, showed increased
responses, more epitopes within the ecto-domain region of p15E
subunit showed increased response post-vaccination in KoRV-
infected koalas (Fig. 6).
DISCUSSION
Two main infectious diseases, Chlamydia and KoRV, including a
potential interaction between them, pose a significant threat to
the long-term survival of the koala. KoRV-related lymphomas have
been reported in several captive populations and, while not as
prevalent, also occur in wild koala populations.6,7 KoRV has also
been shown to be associated with chlamydial disease in wild
koalas.10 In addition to losses in wild koalas, both diseases also
cause significant morbidity and mortality in captive animals. While
quarantine and antiretroviral drug treatment are possible control
measures, they are generally impractical in a wild animal such as
the koala, leaving vaccination as the only realistic option. In this
study, we examined the effect of a recombinant envelope protein-
Fig. 4 Vaccine-induced neutralizing activity of koala serum as
measured by KoRV infection of 293T cells in the presence of koala
sera. All post-vaccination serum samples (n= 6) were assayed and
compared to pre-vaccination samples (mean values and standard
deviation are indicated by horizontal lines and error bars,
respectively). KoRV-negative samples are shown in open circles
while KoRV-positive samples are shown in shaded circles. The level
of significance was measured as ****p < 0.0001 using Student’s T test
(p ≤ 0.05)
Fig. 5 Change in KoRV viral RNA load following vaccination in KoRV-infected koalas as measured by RT-qPCR. a Absolute KoRV viral load in
each KoRV-positive koala over the trial period. b KoRV viral load presented as percentage of pre-vaccination in KoRV-positive koalas (n= 3)
over time (mean ± SEM are represented by horizontal lines and error bars). The level of significance was measured as ***p= 0.0003 and ****p
< 0.0001 using Student’s T test (p ≤ 0.05)
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based anti-KoRV vaccine in koalas, either naturally infected with
KoRV-A or KoRV free. Our results show that vaccination can be
successful for both KoRV-negative and KoRV-positive koalas. All
vaccinated animals produced significant levels of circulating anti-
KoRV antibodies. We showed that these antibodies had a
neutralizing effect in an in vitro assay, but more importantly, we
showed that vaccination had a therapeutic effect on koalas
infected with KoRV by significantly reducing the circulating viral
load. We also identified B-cell epitopes that were differentially
recognized in KoRV-infected versus KoRV-free koalas following
vaccination.
Using the same recombinant protein that was used as the
vaccine immunogen, rEnv, we successfully developed an ELISA to
measure the KoRV-specific serum IgG response following vaccina-
tion. We found that our vaccine formulation induced a significant
antibody response in all six koalas. This finding is consistent with a
small preliminary trial22 that was conducted in Queensland koalas
with endogenous KoRV-A infection where vaccination was shown
to induce an immune response. In our current trial, we purposely
chose South Australian animals that were infected with what is
assumed to be exogenous KoRV, as well as those that were KoRV
negative, to compare the immune responses to vaccination. We
found that the antibody levels 3 months post-vaccination
remained significantly higher than pre-vaccination levels and the
average response was comparable in both KoRV-positive and
-negative animals. This finding demonstrates that the recombi-
nant protein vaccine antigen is effective in stimulating immune
response in naturally infected koalas.
A key finding of our study was that all the vaccinated koalas,
both KoRV free as well as those exogenously infected with KoRV,
produced vaccine-induced antibodies that were able to neutralize
KoRV in an in vitro assay. We also found that the levels of
neutralizing antibodies produced following vaccination were
similar in both KoRV-negative and KoRV-infected koalas. This is
strongly encouraging for KoRV vaccine development. The p15E
subunit of the envelope protein has been shown in other studies
to induce the production of neutralizing antibodies following
vaccination against other retroviruses such as FeLV, FIV, PERVs,
HIV-1, SRV-1,23–27 with the KoRV p15E subunit, in particular, shown
to induce neutralizing antibodies in rats.28 As this is an
encouraging finding, it will be interesting to determine if the
antibodies produced against this subunit represent broadly
neutralising antibodies. KoRV, like other retroviruses, has been
shown to possess sequence type variations in the envelope
protein,29 and these variations have been used for classification
purposes.4,30 Although we tested the ability of the post-
vaccination serum to neutralize KoRV-A variant only, the possibility
of the serum to neutralize other KoRV variants must also be
investigated.
Following the promising antibody response to vaccination,
particularly the neutralizing ability, we characterized the specificity
of the antibodies to epitopes within the env protein using
PepScan methodology. The protein contains epitopes which are
responsible for the production of neutralizing antibodies in FeLV,
FIV, PERVs, HIV-1, and SRV-1. The p15E region contains hydrophilic
domains which provide stronger water solubility and stronger
polarity. Both properties make the recombinant protein a suitable
vaccine antigen. We found two distinct epitope profiles in the
p15E subunit region following vaccination. Following vaccination,
KoRV-negative koalas produced antibodies specific to epitopes
only in the endo-domain region of the p15E subunit of the env
protein. While previous studies have targeted the ecto-domain
region of the transmembrane protein of retroviruses for the
induction of neutralizing antibodies,31 this study showed that
epitopes on the endo-domain region of the transmembrane
protein may also induce production of neutralizing antibodies.
Koalas naturally infected with KoRV, on the other hand, produced
antibodies against epitopes mainly in the ecto-domain but also a
few epitopes in the endo-domain of the transmembrane protein.
It was interesting to find that koalas differentially recognize B-cell
epitopes following KoRV vaccination based on previous exposure
to KoRV, and this finding could prove to be very important in
future design of KoRV vaccines by targeting specific peptides for
KoRV-infected or KoRV-negative animals.
Another important finding in this study was a steady reduction
in KoRV viral RNA load over the trial period in all three KoRV-
infected koalas following vaccination. While the production of
antibodies, including neutralizing antibodies, following vaccina-
tion is promising, the most critical requirement of a vaccine is
whether it can reduce the viral load in infected animals. Viral loads
in infected animals dropped by an average of 48% by 8 weeks
post-vaccination and by 79% by 12 weeks post-vaccination. We
consider this reduction to be quite significant considering the
relatively short time frame (12 weeks) post-vaccination. Although,
we could not measure the responses at longer times due to ethical
limitations of holding the koalas for longer periods, we expect that
this trend in viral load reduction levels would continue. This is
highly encouraging for future therapeutic KoRV vaccine
development.
Fig. 6 List of epitopes across the p15E subunit of the KoRV env protein recognized post-vaccination by KoRV-positive and KoRV-negative
koalas+ Recognized epitopes; - unrecognized epitopes; FP fusion peptide; HR1 heptad repeat 1; IS immunosuppressive domain, HR2 heptad
repeat 2, MP membrane proximal external region, TM transmembrane region, CP cytoplasmic tail, R-P R-peptide.
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Viral load has been shown to correlate with disease progression
in other retroviruses such as FIV, HIV-1, and SIV,32–34 and
transmission in HIV.35 While there has not yet been any direct
study on koala disease outcome in response to manipulation of
KoRV viral load, a related study does exist.7 It was shown that KoRV
viral loads were significantly higher in koalas with leukemia or
lymphoma, relative to healthy animals. Therefore, the assumption
is that reducing viral loads should reduce the associated disease
progression. The reduction in viral load reported in this study
might be important in delaying KoRV-associated disease progres-
sion as well as reducing the KoRV transmission rate, since
exogenous transmission is presumably dependent on viral load.
Therapeutic vaccines represent a promising approach in the effort
to enhance immunogenicity, reduce bacterial and viral load in
both human and animal infections, and reduce pathogen
associated morbidity and mortality.20,21,36–39 The importance of
a therapeutic vaccine, especially in a single dose format, becomes
even more apparent in the case of wild koalas where antiretrovir-
als do not represent a viable option in treating KoRV infections.
The results of this study suggest that the therapeutic effect seen in
this trial population, though limited in size, should be applicable
to a larger population of koalas, thus making our vaccine suitable
for use in the wild. While our results are promising, we recognize
that further work is needed to refine the vaccine into a single
dosage to suit wild koalas. Nevertheless, the vaccine could
potentially be used in its current form in koalas which are KoRV
negative or exogenously infected with KoRV-A. These koalas are
an important subgroup of animals to protect against KoRV with
the aim of preventing or delaying further KoRV transmission,
associated disease, and/or endogenization. Such koalas exist in
South Australia and Victoria.
The long-term survival of the koala is under threat from many
human causes (such as habitat destruction) as well as infectious
disease, chiefly Chlamydia and KoRV. KoRV is spreading through
the Australian koala population, apparently from north to south,
with 100% of northern koalas infected (endogenously) but only
around 50% of southern animals currently infected (exogenously).
A vaccine that could be effective, even in just exogenously
infected koalas, would be a major advance. Our results
demonstrate very promising progress in the development of an
effective anti-KoRV vaccine in both naïve as well as exogenously
infected animals. The next stage will be to evaluate this vaccine in
endogenously infected koalas. Vaccines against other retroviruses,
such as FeLV, have been shown to be successful and if an equally
successful vaccine can be developed for koalas, then this should
have a significant impact on saving the species.
MATERIALS AND METHODS
Preparation of recombinant KoRV Env protein
The Env protein of KoRV, based on the multiple alignment of available
KoRV sequences in GenBank (http://www.ncbi.nlm.nih.gov/), was opti-
mized for expression in Escherichia coli (Fig. 1a and b). The optimized gene
was synthesized and cloned into pGEX-4T1 with Bam HI and Sal I
restriction sites at the 5′ and 3′ ends of the gene, respectively. The correct
sequence of the construct was confirmed by sequencing at both forward
and reverse directions (AGRF, Adelaide). The expression vector carried
Glutathione S-transferases (GST) for further affinity purification. The
recombinant vector was transformed into E. coli, BL21 cells. For the
expression of the recombinant protein, a fresh subculture of the
transformed cells was cultured in a rich Luria-Bertani Medium (10 g
Tryptone, 10 g NaCl, 5 g yeast extract, and 0.1% D-glucose per liter of
distilled water) containing 30mg/ml of filtered sterile Ampicillin, then
induced by adding 0.3 mM isopropyl b-D-1-thiogalactopyranoside (IPTG)
(Sigma, St Louis, MO, USA) with subsequent incubation for 3 h at 250 rpm
at 37 °C. The culture suspension was centrifuged at 5000×g for 20 min at
4 °C in (Sorvall RC 5B centrifuge). The supernatant was discarded, and the
cells were resuspended in cold lysis buffer (20mM Tris HCl pH 8.0, 300mM
NaCl, 1 mM 2-mercaptoethanol, and 5% Triton X-100). To lyse the cells, a
final concentration of 60 µg/ml lysozyme and 200 µg/ml DNase I were
added to the cell suspension and incubate on ice for 20min till the liquid
turns to a non-viscous and cleared lysate. The suspension was centrifuged
at 8000×g at 4 °C for 10min. The supernatant was filtered through 0.22 µM
syringe filters and used for affinity purification chromatography. The
obtained cell lysate containing GST-Env-Trans protein was loaded onto a
GST column (GE Healthcare, life sciences) and washed to remove all other
impurities. The GST-ENV-Trans protein eluted with column buffer contain-
ing 20mM Glutathione (Sigma, St Louis, MO, USA). The purified protein
was desalted and concentrated by ultrafiltration in Vivaspin size exclusion
centrifugal membrane tube with cut-off 20,000 Dalton (Sartorius Stedim
Biotech, Goettingen Germany). Protein concentration of the GST-Env-Trans,
hereafter denoted by rEnv, was measured using NanoDrop, adjusted at
100mg/ml and stored in aliquots at −70 °C. To analyze the purified
protein, 10 µl of the protein was run in a 12% discontinues odium dodecyl
sulfate polyacrylamide gel electrophoresis.
Adjuvant
The adjuvant used was a three-compound mixture that consists of
polyphosphazine (PCEP), host defense peptide 1002, and poly I:C (Vaccine
and Infectious Disease Organization, Saskatchewan, Canada).40 Each dose
of vaccine was prepared as per Khan et al.40 with sterile phosphate
buffered saline (PBS) to contain 50 µg of rEnv, with 250 µg each of PCEP,
poly I:C, and 500 µg of peptide 1002.
Immunization and sample collection
Six healthy koalas, as assessed by veterinary staff and blood biochemical
parameters from the Mount Lofty population in South Australia, were
housed temporarily at the Adelaide Koala and Wildlife Hospital (Plympton,
South Australia) whilst awaiting release following veterinary treatment for
minor conditions and used for this study. The koalas were assigned into
two groups based on their KoRV infection PCR status: (a) KoRV positive or
(b) KoRV negative. Animals in both groups were vaccinated subcuta-
neously on day 0 and received a booster shot at 4 weeks. Four milliliters of
whole blood was collected on day 0 (prior to vaccination), and at weeks 8
and 12 post-vaccination. Blood samples beyond 12 weeks post-vaccination
could not be obtained due to regulations related to holding koalas in
captivity for longer periods; 500 µl of whole blood was stored at −20 °C for
genomic DNA extraction for KoRV infection status. Serum and plasma
samples were obtained and 100 µl of plasma was placed into RNALater at
−20 °C for quantification of KoRV viral RNA load. All animal work was
approved by University of the Sunshine Coast Animal Ethics Committee
(AN/A/16/106), University of Adelaide Animal Ethics Committee (S-2016-
053) and the South Australian Government (Department of Environment,
Water and Natural Resources scientific purposes permit, E26513-1).
KoRV genotyping and estimation of proviral copy number
All koalas were screened for KoRV infection using a genomic DNA
conventional PCR assay and quantitative PCR of viral RNA extracted from
plasma as per ref. 10 The additional qPCR step was conducted to confirm
that any koala designated as being KoRV positive is not merely carrying
replication defective KoRV as it has been suggested that some South
Australian koalas may test positive for a target proviral gene but not
express the same at the transcriptome level.41 Briefly, PCR primers were
designed to amplify part of the highly conserved polymerase (pol) gene to
confirm the presence or absence of KoRV infection, while the variable
region A and transmembrane p15e domain of the KoRV envelope (env)
gene were used to differentiate between KoRV-A and KoRV-B virus types.10
To confirm the specificity of our KoRV-A specific PCR assay, the PCR
products from the three positive animals were sequenced (Macrogen Inc.)
and matched to the published KoRV-A sequence (Genbank accession
AF151794). Proviral copy number was quantified as per ref. 2
Total KoRV viral RNA PCR and quantification
Viral RNA was extracted from the plasma stored in RNALater using the
Qiagen viral RNA mini kit (Qiagen). Contaminating DNA was removed with
Amplification Grade DNase I (AMPD1; Sigma). Viral RNA load was thereafter
quantified using QuantiTect SYBR Green RT-PCR Kit (Qiagen). For
quantification of viral RNA, standards of known concentration (108 to
101) of KoRV env gene plasmid prepared by Integrated DNA technologies
(Coralville, Iowa, USA), were prepared for each run and the results were
normalized against the standard curve. PCR reactions were carried out
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using CFX 96 Touch System (Bio-Rad, Australia) under the following
conditions: env; 50 °C for 30min, 95 °C for 15min (1 cycle), 94 °C for 15 s,
54 °C for 30 s, 72 °C for 30 s (50 cycles). All procedures were carried out
following the manufacturers’ instructions.
KoRV-specific IgG response ELISA
To characterize accurately anti-KoRV antibodies following vaccination, we
removed any serum antibodies that may be directed against the GST
component of the rEnv used for both vaccination and immunoassay. We
coated 96-well ELISA plates (Clear Flat-Bottom Immuno Nonsterile;
ThermoFisher Scientific, Aus) with 1 µg GST and incubated at room
temperature for 2 h. The plate was thereafter washed three times with PBS
containing 0.05% Tween-20, and incubated with serum samples at 4 °C
overnight. Serum samples were collected afterwards and used in the ELISA
described below; 96-well ELISA plates (Clear Flat-Bottom Immuno
Nonsterile; ThermoFisher Scientific, Aus) were coated overnight at 4 °C
with 1 µg rEnv in PBS and blocked for 1 h at 37 °C with 5% skim milk in PBS
containing 0.05% Tween-20 (smPBST) on a shaker. Serum samples were
serially diluted two-fold in smPBST, with a starting dilution of 1:100, added
to wells and incubated on a shaker at 37 °C for 1 h. Sheep anti-koala IgG
diluted 1:5000 in smPBST was added to the plates and incubated on a
shaker for 1 h at 37 °C. Thereafter donkey anti-sheep HRP IgG (In Vitro
Technologies, Aus) diluted 1:1000 in smPBST was added and incubated for
a further 1 h at 37 °C on a shaker. The plate was washed three times with
PBS containing 0.05% Tween-20 (PBST) after each step; 100 µl of
Tetramethylbenzidine (TMB) Liquid Substrate (Sigma-Aldrich) was added
and the reaction was stopped after 3 min with 100 µl of 1 m H2SO4. Optical
density was read at 450 nm (EnSpire Multimode Plate Reader, PerkinElmer,
Australia) and end-point titers thereafter calculated (GraphPad Prism 6.01).
Anti-KoRV MPER peptide IgG ELISA
A peptide designated as KoRV MPER and containing 31 amino acids
(LKERLDKRQL EHQKNLSWYE GWFNRSPWLT T), representing the MPER of
KoRV envelope protein (Fig. 1b), designed by our group and synthesized
(95.4% purity) by VCPBIO (Shenzhen, China) was used to coat 96-well ELISA
plates at a concentration of 1 µg in bicarbonate buffer for 1 h at 37 °C on a
shaker. The plate was washed three times in PBST and thereafter blocked
with smPBST. Serially diluted sera were added and incubated at 37 °C on a
shaker for 1 h. All other reactions proceeded as per KoRV-specific IgG
response ELISA described above.
Design of biotinylated KoRV p15E peptide library
The p15E sequence of KoRV envelope protein (464–659 AA) was used to
design 63 overlapping 15mer peptides with 3 amino acids offset. We
designed the peptides to span both the full length of ecto- and endo-
domains of the p15E subunit of KoRV envelope protein (Fig. 1c). Each
biotinylated peptide (constructed by Mimotopes; Melbourne, Australia)
contained a hydrophilic tetrapeptide, SGSG between the biotin and
sequence of interest.
KoRV p15E epitope mapping ELISA
Wells of streptavidin-coated 96-well plate (Mimotopes, Aus) were coated
with individual peptide at a concentration of 2 µg/well in PBS containing
0.1% Tween-20 (PBST) and incubated for 2 h at room temperature on a
shaker. Then the plate was washed four times with PBST and coated for 4 °
C overnight with plasma samples diluted 1:50 in PBST. Post-incubation, the
plate was washed four times in PBST and a secondary antibody, sheep anti-
koala IgG, was added at a dilution of 1:5000 in PBST and incubated for 1 h
at room temperature on a shaker, and thereafter washed four times in
PBST. A detecting antibody, donkey anti-sheep HRP IgG (In Vitro
Technologies, Aus), diluted 1:1000 in PBS was added and incubated for a
further 1 h at room temperature on a shaker. The plate was then washed
four times with PBST and a further two times with PBS to remove traces of
tween-20; 50 µl of 1-Step™ ABTS Substrate Solution (2,2′-Azinobis [3-
ethylbenzothiazoline-6-sulfonic acid]-diammonium salt, ThermoFisher
Scientific, Aus) was added and incubated at room temperature for
10min. Color development was measured at an optical density of 405 nm
wavelength (EnSpire Multimode Plate Reader, PerkinElmer, Australia). Data
analysis was performed as per ref. 42
KoRV in vitro neutralization assay
Prior to setting up KoRV in-vitro neutralization assay, we isolated KoRV
virus stock. Briefly, concanavalin A-stimulated PBMC from KoRV-A-infected
Queensland koala was cocultured with HEp2 cell line. Afterwards, filtered
supernatant was collected and added to fresh HEp2 culture. Filtered
supernatant from infected HEp2 cells were passaged five times. To confirm
infectivity, filtered supernatant from infected HEp2 cells was added to HEK
293T cell line and passaged six times. Filtered supernatant from both HEp2
and 293T cultures were tested by PCR for presence of KoRV and
designated as KoRV virus stock. To confirm the specificity of isolated
KoRV, the PCR products were sequenced (Macrogen Inc.) and matched to
the published KoRV sequences. KoRV in vitro neutralization assay was
performed as per ref. 43 Briefly, serum samples decomplemented by
heating in a water bath at 56 °C for 30min, and diluted at a ratio of 1:20 in
cell culture medium. KoRV virus stock was added, at a ratio of 1:2, to serum
samples and incubated for 30min at 37 °C under 5% CO2. Virus stock that
gave a Cq value of 25–27 was used for infection. Culture medium was
removed from HEK 293T cells (ATCC, CRL-11268) seeded in 96 well plates
(Greiner bio one; Interpath, West Heidelberg, Australia) and grown until
they reached 50–60% confluence, and replaced with serum samples. The
culture was incubated for 65 h at 37 °C under 5% CO2. Post-incubation, the
cells were harvested, genomic DNA was extracted using QiaAmp DNA mini
kit (Qiagen) following the manufacturer’s instructions, and analyzed for
KoRV proviral integration. Total proviral load was then quantified as per ref.
10 Neutralization was determined by comparing the proviral load of
infected cells in the presence of post-immunized serum samples to pre-
immunized samples.
Data availability
The data that support the findings of this study are available from the
authors on reasonable request.
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